NCT05010174View on ClinicalTrials.gov

Long-term Safety Follow-up in Recipients Who Previously Received Medeor's Cellular Immunotherapy Products

TerminatedOBSERVATIONAL
Enrollment

5

Participants

Timeline

Start Date

May 11, 2022

Primary Completion Date

April 30, 2024

Study Completion Date

April 30, 2024

Conditions
Immune Tolerance
Interventions
DRUG

MDR product

Observation of patients previously receiving MDR product(s)

Trial Locations (1)

06519

Yale University, New Haven

Sponsors
All Listed Sponsors
lead

Medeor Therapeutics, Inc.

INDUSTRY